Allergy testing: the role of recombinant allergens

Area of Science:

• Molecular biology and immunology
• Allergy diagnostics and therapeutics

Background:

• Traditional allergy diagnosis relies on crude allergen extracts, identifying sources but not specific disease-eliciting molecules.
• Limitations in pinpointing exact allergens hinder precise diagnosis and targeted treatment strategies for type I allergies.

Purpose of the Study:

• To explore the advancements in allergy diagnosis and treatment utilizing recombinant allergens.
• To highlight the role of component-resolved diagnosis (CRD) in personalized allergy management.
• To assess the application of recombinant allergens in specific immunotherapy and vaccine development.

Main Methods:

• Production of recombinant allergens through molecular biology techniques.
• Application of recombinant allergens in in vitro diagnostic tests for component-resolved diagnosis (CRD).
• Development of chip-based allergy tests for simultaneous detection of numerous allergens and epitopes.
• Monitoring of immunotherapy efficacy via measurement of allergen-specific IgG antibodies.

Main Results:

• Recombinant allergens enable precise identification of individual patient reactivity profiles.
• Chip-based tests allow simultaneous analysis of thousands of allergens and epitopes.
• Recombinant allergen-based tests improve patient selection for specific immunotherapy and enable monitoring of treatment efficacy.
• Recombinant allergens and their derivatives show promise as vaccines for type I allergy treatment.

Conclusions:

• Recombinant allergens have transformed type I allergy diagnosis, enabling component-resolved diagnosis (CRD).
• These advancements facilitate personalized immunotherapy selection and efficacy monitoring.
• Recombinant allergens represent a significant step forward in both diagnosing and treating type I allergies.